Olympus Corporation concluded an agreement with Revival Healthcare Capital, a medtech investment firm, to co-found Swan EndoSurgical, a company dedicated to the development of a robotic system for gastrointestinal care. Olympus will take a significant equity stake in the company, with a combined initial investment of at least $65 million. The total combined funding could reach up to $458 million if pre-agreed milestones are met and the program reaches term. Endoluminal robotics aims to advance the capabilities of endoscopic procedures which yield early and accurate diagnoses of conditions such as GI tract cancer. An endoluminal robot is able to easily maneuver the GI tract and deploy flexible arms, providing opportunities for increased safety and more effective procedures, potentially avoiding invasive surgery. “This will allow the delivery of transformative, organ-sparing care that enhances outcomes for a broad patient population,” said Bob White, president and CEO at Olympus. Headquartered in the U.S., Swan EndoSurgical has assembled a leadership team of industry professionals who will drive technical, clinical, and commercial development of the robotic platform.